Baron, C.; Buchholz, M.; Majchrzak-Stiller, B.; Peters, I.; Fein, D.; Müller, T.; Uhl, W.; Höhn, P.; Strotmann, J.; Braumann, C.
Substance GP-2250 as a New Therapeutic Agent for Malignant Peritoneal Mesothelioma—A 3-D In Vitro Study. Int. J. Mol. Sci. 2022, 23, 7293.
https://doi.org/10.3390/ijms23137293
AMA Style
Baron C, Buchholz M, Majchrzak-Stiller B, Peters I, Fein D, Müller T, Uhl W, Höhn P, Strotmann J, Braumann C.
Substance GP-2250 as a New Therapeutic Agent for Malignant Peritoneal Mesothelioma—A 3-D In Vitro Study. International Journal of Molecular Sciences. 2022; 23(13):7293.
https://doi.org/10.3390/ijms23137293
Chicago/Turabian Style
Baron, Claudia, Marie Buchholz, Britta Majchrzak-Stiller, Ilka Peters, Daniel Fein, Thomas Müller, Waldemar Uhl, Philipp Höhn, Johanna Strotmann, and Chris Braumann.
2022. "Substance GP-2250 as a New Therapeutic Agent for Malignant Peritoneal Mesothelioma—A 3-D In Vitro Study" International Journal of Molecular Sciences 23, no. 13: 7293.
https://doi.org/10.3390/ijms23137293
APA Style
Baron, C., Buchholz, M., Majchrzak-Stiller, B., Peters, I., Fein, D., Müller, T., Uhl, W., Höhn, P., Strotmann, J., & Braumann, C.
(2022). Substance GP-2250 as a New Therapeutic Agent for Malignant Peritoneal Mesothelioma—A 3-D In Vitro Study. International Journal of Molecular Sciences, 23(13), 7293.
https://doi.org/10.3390/ijms23137293
